External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

JSMO 2025

March 06 - March 08

Kobe, Japan

site2.convention.co.jp

Add to calendar

Medical Materials

Agenda

Coming soon

05:00 AM

Duration 15mins Japan

Pharmacokinetics and safety of adjuvant alectinib in Japanese patients (pts) from ALINA with resected ALK-positive NSCLC

Horinouchi H, Kato T, Sugawara S, Tanaka H, Kawamura T, Yamamoto H, Sakagami T, Cardona A, Xu T, Hiles L, Sutaria D, Nishio M

Oncology | Lung Cancer

Add to calendar

Duration 1hr Japan

Resistance mechanisms and efficacy of first-line alectinib in patients with ALK+ non-small cell lung cancer

Go Saito, Hidekazu Suzuki, Yasushi Goto, Ken Tajima, Hiromi Nagashima, Tetsunari Hase, Takaaki Sasaki, Yasutaka Watanabe, Hirotsugu Kenmotsu, Shoichi Itoh, Masafumi Yamaguchi, Marie Matsumoto, Yosuke Seto, Ken Uchibori, Hidetoshi Hayashi, Eisaku Miyauchi, Naoki Ishizuka, Yusuke Kajihara, Yuki Nakagawa, Ryohei Katayama

Oncology | Lung Cancer

Add to calendar

06:30 AM

Duration 1hr Japan

Third OS interim analysis from BEAT-SC: Addition of bevacizumab to atezolizumab & chemotherapy in patients with ES-SCLC

Shoichiro Yamamoto, Yuichiro Ohe, Baohui Han, Makoto Nishio, Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, Gaofeng Li, Nobuyuki Katakami, Xianling Liu, Yuki Nakagawa, Masaya Sasaki, Toshihiro Nanki, Chunyu Qian, Nobuyuki Yamamoto

Oncology | Lung Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.